Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2452

Sort by

Sort Order Select

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Dennis Cooper, MD, Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD PhD, Tracy Krimmel, AOCN, APRN-BC, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 4485.

https://doi.org/10.1182/blood-2019-130598

Published: 2019

Journal Articles

Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT

Annalisa Paviglianiti, MD, Myriam Labopin, MD, Didier Blaise, MD PhD, Gerard Socie, MD PhD, Claude-Eric Bulabois, MD, Celestine Simand, MD, Nathalie Fegueux, MD, Armin Gerbitz, MD, Gaëlle Guillerm, MD, Johan Maertens, Patrice Chevallier, MD, Anne Huynh, MD, Pascal Turlure, MD, Eric Deconinck, MD PhD, Edouard Forcade, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 4548.

https://doi.org/10.1182/blood-2019-122251

Published: 2019

Journal Articles

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Janny M. Yao, PharmD, Dongyun Yang, PhD, Saloomeh Mokhtari, Amandeep Salhotra, MD, Haris Ali, MD, Shukaib Arslan, MD, Salman Otoukesh, MD, Ibrahim Aldoss, MD, Karamjeet S. Sandhu, MD, Anthony Stein, MD, David Snyder, MD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2019) 134 (Supplement_1): 4518.

https://doi.org/10.1182/blood-2019-129221

Published: 2019

Journal Articles

Mapping the Road of Gvhd and GVT: A Longitudinal Study of Immune-Transcriptome Signatures As Novel Approach to Solve Post-Allogeneic Hematopoietic Cell Transplantation Dilemmas

Merav Bar, MD, Alice Woo, Mohammed Toufiq, Sabri Boughorbel, Darawan Rinchai, Mohammed Elanbari, Valentina Mattei, Rebecca Mathew, Irene Cavattoni, MD, Sabine Forer, Marco Zecca, Patrizia Comoli, Giovanni Grillo, MD, Catherine Cole, Chiara Cugno, MD, Sara Tomei, PhD, Damien Chaussabel, Sara Deola

Blood (2019) 134 (Supplement_1): 4550.

https://doi.org/10.1182/blood-2019-122884

Published: 2019

Journal Articles

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Akanksha Chichra, DNB, Lingaraj Nayak, MDDM MDcal Oncology, Rushabh Kothari, MD DM MDcal Oncology, Siddhesh Arun Kalantri, MD, Avinash Bonda, MD DM, Anant Gokarn, MD, Sachin Punatar, MBBS,MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Sadhana Kannan, MSc, Libin J Mathew, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4493.

https://doi.org/10.1182/blood-2019-128099

Published: 2019

Journal Articles

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Benedetta Rambaldi, MD, Carol Reynolds, PhD, Sharmila Chamling Rai, BSc, Takeru Asano, MD PhD, Yohei Arihara, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Corey Cutler, MD MPH, FRCPC, Sarah Nikiforow, MD PhD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Joseph H. Antin, MD, Rizwan Romee, MD PhD, Robert J. Soiffer, MD, Domenico Russo, MD, Jeanette Ampudia, BSc, Cherie Tracy Ng, PhD MPH, Stephen Connelly, PhD MBA, Jerome Ritz, MD

Blood (2019) 134 (Supplement_1): 4517.

https://doi.org/10.1182/blood-2019-125721

Published: 2019

Journal Articles

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Relapse-Free and Overall Survival

Dipenkumar Modi, MD, Vijendra Singh, MD, Seongho Kim, PhD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2019) 134 (Supplement_1): 4488.

https://doi.org/10.1182/blood-2019-125418

Published: 2019

Journal Articles

Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 4551.

https://doi.org/10.1182/blood-2019-122894

Published: 2019

Journal Articles

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Francesco Mazziotta, MD, Gabriele Buda, MD PhD, Nadia Cecconi, MD, Giulia Cervetti, MD, Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Matteo Pelosini, MD PhD, Edoardo Benedetti, MD, Francesco Caracciolo, MD, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2019) 134 (Supplement_1): 3254.

https://doi.org/10.1182/blood-2019-126118

Published: 2019

Journal Articles

Use of Ex Vivo Graft Manipulation and Posttransplant Cyclophosphamide Result in Low GvHD Rates and Acceptable Engraftment after RIC Regimens in Pediatric Mismatched SCT

Peter Lang, MD, Michaela Döring, PD Dr. MD, Anne-Marie Lang, M.Sc., Patrick Schlegel, Dr. MD, Christian M. Seitz, Dr. MD, Robin Fischer, Dr. rer. nat., Ursula Holzer, PD Dr. MD, Ines Brecht, PD Dr. MD, Rupert Handgretinger, MD

Blood (2019) 134 (Supplement_1): 3255.

https://doi.org/10.1182/blood-2019-129654

Published: 2019

Journal Articles

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation: Comparing Post-Transplant Cyclophosphamide Versus Anti-T-Lymphocyte Globulin As Graft-Versus-Host Disease Prophylaxis in a Retrospective Cohort Study

Rashit Bogdanov, PhD, Saskia Leserer, Evren Bayraktar, PhD, Nikolaos Tsachakis-Mück, Lara Kasperidus, PhD, Markus Ditschkowski, PhD, Dietrich W. Beelen, Amin T. Turki, MD PhD

Blood (2019) 134 (Supplement_1): 3289.

https://doi.org/10.1182/blood-2019-130623

Published: 2019

Journal Articles

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Mohamad Sobh, PharmD, Lothar B. Huebsch, MD, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MDPhDMRCPI FRCPath(UK), Sultan Altouri, MDFRCPC, Michael Kennah, MD, Elizabeth Drouin, MD, David S. Allan, MD FRCPC, MSc, Harold Atkins, MD, Grace Christou, MD, Pierre Villeneuve, MD PhD, Alexandre P.Blanchard, PhD, Kelsey Maclellan, Ranjeeta Mallick, PhD MSc, BSc, Nicole B. Laferriere, MD PhD, Sathish Gopalakrishnan, MD, Sita D. Bhella, MD, Natasha Kekre, MDFRCPC, Christopher Bredeson, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3263.

https://doi.org/10.1182/blood-2019-122436

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Francesco Saraceni, Myriam Labopin, MD, Riitta Niittyvuopio, Gerard Socie, MD PhD, Nicolaus Kröger, Edouard Forcade, MD, Paul V Browne, MB,FRCPath, Péter Reményi, Jan J Cornelissen, MD PhD, Stephen Robinson, MBBS, PhD BSc, Ibrahim Yakoub-Agha, MD PhD, Thierry Lamy, PhD MD, Eolia Brissot, MD PhD, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 3327.

https://doi.org/10.1182/blood-2019-127810

Published: 2019

Journal Articles

Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia

Biju George, MDDM, Aby Abraham, MD DM, Anu Korula, MD DM, Anup Devasia, MD DM, Kavitha M Lakshmi, MSc, Uday Prakash Kulkarni, MD DM, Fouzia N Abu Backer, MD DM, Alok Srivastava, MD,FRACP,FRCPA, Vikram Mathews, MD DM

Blood (2019) 134 (Supplement_1): 3272.

https://doi.org/10.1182/blood-2019-129328

Published: 2019

Journal Articles

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Hany Elmariah, MD MS, Syeda Mahrukh Hussnain Naqvi, MD MHS, Jongphil Kim, PhD, Taiga Nishihori, MD, Asmita Mishra, MD, Lia Perez, MD, Hien D. Liu, MD, Farhad Khimani, MD, Michael Nieder, MD, Joseph Pidala, MD, Nelli Bejanyan, MD

Blood (2019) 134 (Supplement_1): 3329.

https://doi.org/10.1182/blood-2019-129437

Published: 2019

Journal Articles

Stroke Risk in Blood or Marrow Transplant (BMT) Survivors - a Report from the BMT Survivor Study (BMTSS)

Radhika Gangaraju, MD, Yanjun Chen, MS, Lindsey Hageman, MPH, Jessica Wu, MPH, Wendy Landier, PhD CRNP, Liton F. Francisco, BS, Andrew McDonald, Donna Murdaugh, PhD, Michelle Kung, MA, Emily Ness, MPH, Daniel J. Weisdorf, MD, Stephen J Forman, MD, Lennie Wong, PhD, Mukta Arora, MD, Saro H. Armenian, DO, MPH, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 3298.

https://doi.org/10.1182/blood-2019-124564

Published: 2019

Journal Articles

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies

Melhem Solh, MD, Scott R. Solomon, MD, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 3333.

https://doi.org/10.1182/blood-2019-131608

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Mapping the Road of Gvhd and GVT: A Longitudinal Study of Immune-Transcriptome Signatures As Novel Approach to Solve Post-Allogeneic Hematopoietic Cell Transplantation Dilemmas

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Relapse-Free and Overall Survival

Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Use of Ex Vivo Graft Manipulation and Posttransplant Cyclophosphamide Result in Low GvHD Rates and Acceptable Engraftment after RIC Regimens in Pediatric Mismatched SCT

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation: Comparing Post-Transplant Cyclophosphamide Versus Anti-T-Lymphocyte Globulin As Graft-Versus-Host Disease Prophylaxis in a Retrospective Cohort Study

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Stroke Risk in Blood or Marrow Transplant (BMT) Survivors - a Report from the BMT Survivor Study (BMTSS)

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only